Prime Medicine (PRME) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prime Medicine (PRME) has outperformed Wave Life Sciences (WVE) over the past year, losing 33.6% versus a loss of 50.8%. Wave Life Sciences is the larger company by market cap ($683.8 million vs $649.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRME | WVE |
|---|---|---|
| Share price | $3.58 | $3.47 |
| Market cap | $649.33M | $683.76M |
| 1-day change | -8.21% | -1.98% |
| YTD return | +12.39% | -79.18% |
| 1-year return | -33.56% | -50.76% |
| 5-year return | — | -31.26% |
| EPS (TTM) | $-1.07 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.65 | $21.73 |
| 52-week low | $2.67 | $3.37 |
| Distance from 52-week high | -46.17% | -84.03% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +98.60% | +420.46% |
| Average volume | 3.32M | 3.10M |
| Shares outstanding | 181.38M | 197.05M |
| Employees | 146 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRME has outperformed WVE by 17.2 percentage points over the past year.
About Prime Medicine
PRME stock →Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 146 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
PRME vs WVE FAQ
Which is bigger, Prime Medicine or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $683.76M compared with $649.33M for Prime Medicine (PRME).
Which stock has performed better over the past year, PRME or WVE?
PRME returned -33.56% over the past 12 months, compared with -50.76% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Prime Medicine and Wave Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Prime Medicine and Biotechnology: Pharmaceutical Preparations for Wave Life Sciences.